-DOCSTART- -X- O
Accumulating -X- _ O
evidence -X- _ O
supports -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
specific -X- _ O
diagnostic -X- _ O
tests -X- _ O
and -X- _ O
antiviral -X- _ O
therapies -X- _ O
for -X- _ O
seriously -X- _ B-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
influenza. -X- _ I-Patient
Among -X- _ O
available -X- _ O
diagnostic -X- _ O
tests -X- _ O
, -X- _ O
reverse-transcriptase -X- _ B-Intervention
polymerase -X- _ I-Intervention
chain -X- _ I-Intervention
reaction -X- _ I-Intervention
is -X- _ O
faster -X- _ B-Outcome
than -X- _ I-Outcome
culture -X- _ I-Outcome
and -X- _ I-Outcome
more -X- _ I-Outcome
sensitive -X- _ I-Outcome
than -X- _ I-Outcome
commercial -X- _ I-Outcome
antigen -X- _ I-Outcome
assays. -X- _ I-Outcome
Current -X- _ B-Intervention
neuraminidase -X- _ I-Intervention
inhibitors -X- _ I-Intervention
were -X- _ O
approved -X- _ O
on -X- _ O
the -X- _ O
basis -X- _ O
of -X- _ O
their -X- _ O
efficacy -X- _ O
in -X- _ O
ambulatory -X- _ O
patients -X- _ O
, -X- _ O
but -X- _ O
seriously -X- _ B-Outcome
ill -X- _ I-Outcome
patients -X- _ I-Outcome
who -X- _ I-Outcome
receive -X- _ I-Outcome
these -X- _ I-Outcome
agents -X- _ I-Outcome
are -X- _ I-Outcome
less -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
die -X- _ I-Outcome
, -X- _ I-Outcome
even -X- _ I-Outcome
when -X- _ I-Outcome
treatment -X- _ I-Outcome
is -X- _ I-Outcome
initiated -X- _ I-Outcome
> -X- _ I-Outcome
48 -X- _ I-Outcome
h -X- _ I-Outcome
after -X- _ I-Outcome
symptom -X- _ I-Outcome
onset. -X- _ I-Outcome
For -X- _ O
patients -X- _ O
hospitalized -X- _ O
with -X- _ O
suspected -X- _ O
influenza -X- _ O
, -X- _ O
it -X- _ O
is -X- _ O
unclear -X- _ O
which -X- _ O
circumstances -X- _ O
warrant -X- _ O
diagnostic -X- _ O
testing -X- _ O
and -X- _ O
which -X- _ O
warrant -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
empirical -X- _ O
therapy. -X- _ O
Rapid -X- _ B-Intervention
antigen -X- _ I-Intervention
assays -X- _ I-Intervention
may -X- _ O
reduce -X- _ B-Outcome
the -X- _ I-Outcome
unnecessary -X- _ I-Outcome
use -X- _ I-Outcome
of -X- _ I-Outcome
other -X- _ I-Outcome
tests -X- _ I-Outcome
and -X- _ I-Outcome
medications -X- _ I-Outcome
but -X- _ I-Outcome
are -X- _ I-Outcome
relatively -X- _ I-Outcome
insensitive -X- _ I-Outcome
, -X- _ O
thus -X- _ O
eliminating -X- _ O
many -X- _ O
patients -X- _ O
with -X- _ O
influenza -X- _ O
as -X- _ O
candidates -X- _ O
for -X- _ O
treatment. -X- _ O
Empirical -X- _ B-Intervention
antiviral -X- _ I-Intervention
therapy -X- _ I-Intervention
ensures -X- _ O
that -X- _ O
all -X- _ B-Outcome
patients -X- _ I-Outcome
receive -X- _ I-Outcome
treatment -X- _ I-Outcome
promptly -X- _ I-Outcome
, -X- _ I-Outcome
at -X- _ I-Outcome
a -X- _ I-Outcome
cost -X- _ I-Outcome
equivalent -X- _ I-Outcome
to -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
diagnostic -X- _ I-Outcome
tests -X- _ I-Outcome
alone -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
results -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
receipt -X- _ I-Outcome
of -X- _ I-Outcome
treatment -X- _ I-Outcome
by -X- _ I-Outcome
many -X- _ I-Outcome
patients -X- _ I-Outcome
without -X- _ I-Outcome
influenza. -X- _ I-Outcome
For -X- _ O
patients -X- _ O
hospitalized -X- _ O
with -X- _ O
suspected -X- _ O
influenza -X- _ O
, -X- _ O
clinicians -X- _ O
need -X- _ O
to -X- _ O
combine -X- _ O
these -X- _ O
approaches -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
optimize -X- _ O
patient -X- _ O
care -X- _ O
. -X- _ O

